Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Multiple Myeloma 11Lymphoma 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Neoplasm Metastasis 9Leukemia 9Neoplasms 8Myelodysplastic Syndromes 8Hodgkin Disease 8Carcinoma, Non-Small-Cell Lung 8Breast Neoplasms 8Lymphoma, Non-Hodgkin 7Leukemia, Myeloid, Acute 7Carcinoma, Renal Cell 7Prostatic Neoplasms 6Melanoma 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Recurrence 5Leukemia, Lymphocytic, Chronic, B-Cell 5Hematologic Neoplasms 5Graft vs Host Disease 5Advanced Cancer 5Unspecified Adult Solid Tumor, Protocol Specific 4Primary Myelofibrosis 4Pancreatic Neoplasms 4Neoplasms, Plasma Cell 4Myeloproliferative Disorders 4Lung Neoplasms 4Leukemia, Myelomonocytic, Chronic 4Leukemia, Myeloid, Chronic-Phase 4Glioblastoma 4

Interventions

talimogene laherparepvec 1Talaporfin 1Sirolimus 1Deoxycholic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neurofibroma × Sirolimus × Clear all
NCT01031901 2012-02-27

Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1)

The University of Texas Health Science Center, Houston

Phase 1 Completed
52 enrolled
CNS

Neurofibroma, Tuberous Sclerosis, Neurofibromatoses, Angiofibroma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡